IBO_OUT_1 [2025-04-03 17:00:23 -0400] 3282 Bytes | 917 tokens | Cum: 917 tkns (11.46% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Impact BioMedical (IBO) hit my radar screen, up to 0.929645 from a prev close of 0.57 Do you think its got more juice or is it lacking potential? It's 5:00:22 PM on Thu Apr 03, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Impact BioMedical (IBO)
IPO: 2024-09-16 (6 Months Ago)
Market Cap: $9,433,243
Shares Outstanding: 12,090,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Here's the first list of news for Impact BioMedical:

C1 - Mar-21-25 02:38PM - Impact Biomedical Inc. Announcement Stock Activity/Pricing
C2 - Feb-26-25 08:30AM - Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality
C3 - Feb-26-25 08:30AM 08:30AM - DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
C4 - Jan-23-25 04:30PM - Impact BioMedical Inc. to Present at The Microcap Conference
C5 - Nov-19-24 08:00AM - Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
C6 - Nov-18-24 07:00AM - Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs
C7 - Nov-11-24 07:30AM - Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health
C8 - Oct-15-24 06:00AM - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease

Prior AI Reports for IBO:
1. 2025-04-01 – Score: 30 – Target: 1.3000 – Highs: 1.3600 / 0.6200 / –
company-struggles-amidst-poor-performance-and-high-insider-ownership
2. 2025-03-21 – Score: 92 – Target: 6.2000 – Highs: 6.1700 / 4.5000 / 4.10
impact-biomedical-soars-despite-sales-drop-targets-50-price-increase
3. 2025-03-20 – Score: 70 – Target: 2.5000 – Highs: 2.4800 / 6.1700 / 4.50
impact-biomedical-shows-mixed-performance-amid-high-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Impact BioMedical (IBO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IBO_OUT_3 [2025-04-03 17:00:27 -0400] 1099 Bytes | 320 tokens | Cum: 1239 tkns (15.49% of 8k)
==========================================================================

Showing C2 (chunk 1 of 4): C2:
**Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality**
Date: Feb-26-25 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/26/3032920/0/en/Impact-Biomedical-Inc-Announces-Acquisition-of-Celios-Protecting-People-Plants-and-Animals-from-the-World-s-Most-Dangerous-Pathogens-With-Clean-Room-Air-Quality.html

February 26, 2025 08:30 ET| Source:IMPACT BIOMEDICAL INCIMPACT BIOMEDICAL INC

HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approxi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_5 [2025-04-03 17:00:28 -0400] 976 Bytes | 302 tokens | Cum: 1608 tkns (20.10% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T17:06:22Z - 11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Ap...
A2 - 2025-04-03T01:06:05Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...
A3 - 2025-04-03T01:06:06Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...
A4 - 2025-04-03T01:06:06Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...
A5 - 2025-04-02T17:06:16Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Allakos (NASDAQ:ALLK), Alumis (NASDAQ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBO_OUT_7 [2025-04-03 17:00:35 -0400] 1098 Bytes | 338 tokens | Cum: 1948 tkns (24.35% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Aptevo Therapeutics (NASDAQ:APVO)**Date: 2025-04-03Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44632127/11-health-care-stocks-moving-in-thursdays-intraday-sessionGainers Protagenic Therapeutics PTIX shares rose 85.8% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $3.0 million. As per the news, the Q4 earnings report came out 3 days ago. OSR Holdings OSRH shares moved upwards by 59.18% to $2.34. The market value of their outstanding shares is at $45.1 million. Aptevo Therapeutics APVO shares rose 45.67% to $2.01. The company's market cap stands at $2.9 million. Alaunos Therapeutics TCRT shares rose 38.75% to $3.88. The market value of their outstanding shares i

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_9 [2025-04-03 17:00:36 -0400] 1055 Bytes | 314 tokens | Cum: 2421 tkns (30.26% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-21T18:38:00Z - Impact Biomedical Inc. Announcement Stock Activity/Pricing
B2 - 2025-02-26T13:30:00Z - Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"
B3 - 2024-12-12T20:56:00Z - Contractor Wins Prestigious Award for Exquisite Ornamental Staircase
B4 - 2024-10-25T11:00:00Z - ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
B5 - 2024-10-15T10:00:00Z - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
B6 - 2024-09-17T15:29:05Z - Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_11 [2025-04-03 17:00:40 -0400] 653 Bytes | 172 tokens | Cum: 2595 tkns (32.44% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Impact Biomedical Inc. Announcement Stock Activity/Pricing**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/21/3047292/0/en/Impact-Biomedical-Inc-Announcement-Stock-Activity-Pricing.htmlImpact BioMedical Inc. announced that there has been no material development in its business affairs not previously disclosed or any other reason to account for the unusual market action regarding its share price.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_13 [2025-04-03 17:00:41 -0400] 1092 Bytes | 295 tokens | Cum: 2939 tkns (36.74% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-03 8-K Item 1.01. Entry Into a Material Definitive Agrmt.

Debt Conversion Agrmt

As previously reported on the Companys current report on Form 8-K, filed March 28, 2025 (the Initial 8-K), Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agrmt (the Debt ...

S3 - 2025-03-28 10-K ITEM 7 - MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

FORWARD-LOOKING STATEMENTS

Certain statements contained herein this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act o...

S4 - 2025-03-28 8-K Item 1.01. Entry Into a Material Definitive Agrmt.

Debt Conversion Agrmt

As previously reported, Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agrmt, dated March 24, 2025, with DSS, Inc., pursuant to that certain Amended and Restated Promisso...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_15 [2025-04-03 17:00:46 -0400] 1047 Bytes | 287 tokens | Cum: 3228 tkns (40.35% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 1.01. Entry Into a Material Definitive Agreement.

Debt Conversion Agreement

As previously reported on the Companys current report on Form 8-K, filed March 28, 2025 (the Initial 8-K), Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agreement (the Debt Conversion Agreement), dated March 24, 2025, with DSS, Inc. (DSS), pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the Promissory Note). The original principal amount of the Promissory Note was $12,000,000, and as of March 24, 2025, the Promissory Note had a principal balance of $13,176,477.03.

In connection with the Initial 8-K, given current market conditions, DSS has withdrawn from the Debt Conversion Agreement at this time. As such, no shares have been issued in connection with the Debt Conversion Agreement....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_17 [2025-04-03 17:00:58 -0400] 4845 Bytes | 1419 tokens | Cum: 4749 tkns (59.36% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+------------------------+------------------------+-------------------------+
| Volume: 5,882,694 | Perf Month: -60.68% | Option/Short: No / Yes | Sales Y/Y TTM: -100.00% |
+--------------------+------------------------+------------------------+-------------------------+
| Avg Volume: 3.81M | Perf Quarter: -68.00% | Short Float: 0.17% | ROE: -167.65% |
+--------------------+------------------------+------------------------+-------------------------+
| Rel Volume: 1.55 | Index: - | Short Ratio: 0.00 | ROI: -580.23% |
+--------------------+------------------------+------------------------+-------------------------+
| RSI (14): 40.33 | Market Cap: 5.34M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+------------------------+------------------------+-------------------------+
| ATR (14): 0.71 | Shs Outstand: 11.50M | Beta: - | EPS Surprise: - |
+--------------------+------------------------+------------------------+-------------------------+
| SMA20: -67.94% | Shs Float: 5.16M | Sales Q/Q: - | P/E: - |
+--------------------+------------------------+------------------------+-------------------------+
| SMA50: -72.35% | Inst Own: 0.77% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+------------------------+------------------------+-------------------------+
| SMA200: -75.78% | Insider Own: 55.15% | Employees: 2 | |
+--------------------+------------------------+------------------------+-------------------------+
| Perf Week: -79.65% | Insider Trans: -33.46% | Debt/Eq: 2.08 | |
+--------------------+------------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: IMPACT BIOMEDICAL INC. (IBO) by Chan Heng Fai Ambrose (Unknown Title) on 2025-03-31
- Common Stock: 300000 shares at $1.028 (I)
- Common stock: 400000 shares at $0.982 (I)
- Common Stock: 650000 shares at $1.447 (I)
- Common Stock: 1176918 shares at $1.08 (I)

Inside Trans: IMPACT BIOMEDICAL INC. (IBO) by DSS, INC. (Unknown Title) on 2025-03-21
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 48281 shares at $3.1292 (D)
- Common Stock: 9858 shares at $3.15 (D)
- Common Stock: 47681 shares at $2.5011 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -24770000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.464
Average Volume: 10342033.96
30-Day High: 4.96
30-Day Low: 0.464

[Detailed Financials: TTM 2024]
- Total Assets: $20,290,000.0
- Total Liabilities: $13,053,000.0
- Total Equity: $7,237,000.0
- Current Assets: $2,448,000.0
- Current Liabilities: $9,785,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,998,000.0

[Detailed Financials: FY 2024]
- Total Assets: $20,290,000.0
- Total Liabilities: $13,053,000.0
- Total Equity: $7,237,000.0
- Current Assets: $2,448,000.0
- Current Liabilities: $9,785,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,998,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

IBO_OUT_19 [2025-04-03 17:01:04 -0400] 676 Bytes | 167 tokens | Cum: 5167 tkns (64.59% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IBO_IN_21 [2025-04-03 17:01:04 -0400] 126 Bytes | 29 tokens | Cum: 5269 tkns (65.86% of 8k)
==========================================================================

====================================
[2025-04-03 17:01:04] # Analysis Completed
Elapsed Time: 41.89 seconds